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Introduction. High-risk prostate cancer represents a therapeutic challenge. The role of radical prostatectomy (RP) in patients with
extreme PSA values is under discussion. Material and Methods. We retrospectively analysed our data of 56 consecutive patients
with preoperative PSA ≥ 40mg/mL undergoing open radical retropubic prostatectomy from 1999 to 2009. Patient survival and
time to PSA recurrence were recorded, and the Kaplan-Meier survival analysis was performed. Postoperative quality of life and
functional status were investigated using a SF-12 questionnaire and determining the number of pads used per day. Results.O v e r a l l
56 patients were available for followup after a median time of 83.84 months. Locally advanced carcinoma was present in 84% while
16% of patients had organ-conﬁned stages. A positive nodal status was observed in 46%. Overall survival was 95% at ﬁve and 81%
at 10 years. Cancer-speciﬁc survival was 100% for ﬁve years and 83% for 10 years. Corresponding biochemical recurrence-free
survival was low (52% and 11%, resp.). Quality of life and functional outcomes were favourable. Conclusions. In patients with PSA
≥ 40mg/mL, RP allows long-term control, exact planning of adjuvant treatment, and identiﬁcation of curable disease.
1.Introduction
Prostate cancer is an important medical issue with a high
complexity regarding stage classiﬁcation and risk-adapted
multidisciplinary treatment. As the consensus towards the
therapy of localised prostate cancer is broad, radical prosta-
tectomy (RP) is an established surgical approach based on
reliable clinical data. High-risk prostate cancer is deﬁned as
PSA > 20ng/mL, Gleason 8–10 or clinical stage ≥ T2c. RP is
also considered as ﬁrst-line treatment for higher-risk strata
whereas the scientiﬁc evidence for patient outcomes, espe-
cially those with elevated PSA values greater than 50ng/mL,
is comparably low [1]. Based on our own single centre
experience and the implementation of available published
data, our investigation targets this relevant clinical topic.
2.MaterialandMethods
We retrospectively analysed our data of 56 consecutive
patients with an elevated PSA ≥ 40ng/mL who underwent
radical retropubic prostatectomy with iliac lymphadenec-
tomy from 1999 to 2009 with followup to October 2010.
The template of LAD consisted in external, internal iliac, and
obturatorial lymph nodes. A nerve-sparing procedure was
not conducted. We examined patient survival, time to PSA
recurrence, and cancer-related survival. Complete followup
was available for 54/56 patients (96%). A Kaplan-Meier
analysis was performed to analyse overall (OS) and cancer-
speciﬁc survival (CSS) and time to biochemical recurrence
(BCR), which was deﬁned as postoperative PSA ≥ 0.4ng/mL
or PSA rise while receiving androgen deferral treatment. To
assess postoperative quality of life, a SF-12 questionnaire was
used. For the evaluation of postoperative continence, the
numberofusedpadsperdaywasinterrogatedusingapatient
questionnaire.
3. Results
In our cohort, 56 consecutive patients with a preoperative
PSA ≥ 40ng/mL (median: 54.2ng/mL) were available for
the analysis. Mean age at surgery was 66.81 years. Median
followup was 83.3 months (IQR: 37.57 to 109.43). Patient
characteristics, the distribution of preoperative staging,
biopsy Gleason’s score, and clinical stages are demonstrated
in Table 1.
With regard to pathological staging, a predominance
of locally advanced cancer is characterized by 84% stage
pT3/pT4 prostate carcinoma whereas, in 16% of patients,2 Advances in Urology
Table 1: Preoperative patient characteristics (IQR: interquartile
range).
n = 56
Age, mean (IQR) 66.81y (61.2–70.1)
PSA, median (IQR) 54.2ng/mL (46–79.1)
Followup, median (IQR) 84.83 months (37.57–109.43)
Gleason’s score (biopsy)
≤6 25 (44%)
7 20 (36%)
8–10 11 (20%)
Clinical stage
cT1 10 (18%)
cT2 9 (16%)
cT3/4 37 (66%)
Table 2: Postoperative patient characteristics.
Pathologic Gleason’s score
≤6 17 (30%)
7 26 (46%)
8–10 13 (24%)
Pathologic stage
pT2 9 (16%)
pT3 20 (36%)
pT4 27 (48%)
Pathologic nodal status
N0 29 (54%)
N+ 25 (46%)
Surgical margin status
Negative 30 (54%)
Positive 26 (46%)
Hormonal therapy
Adjuvant 21 (38%)
Neoadjuvant 17 (30%)
None 18 (33%)
Adjuvant RT
Yes 28 (50%)
No 28 (50%)
Quality-of-life assessment (SF-12): general state of
health
Excellent 6%
Very good 25%
Good 50%
Fair 6%
Poor 13%
Continence assessment (pad usage)
0-1 58%
1 29%
2 or more 13%
the prostate carcinoma was organ conﬁned. A positive nodal
statuswasobservedin46%ofpatientsinourstudycollective.
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Figure 1: Biochemical recurrence.
Pathologic Gleason’s scores of ≤6 were observed in 30% of
cases, the incidence of Gleason’s scores ≥8 was 24%. Surgical
margins were positive in 26 patients (46%). The majority of
patients (68%) underwent additional hormonal treatment,
which was applied according to institutional protocols.
From 1999 to 2004, 17 patients (30%) received neoadjuvant
hormone ablation with LH-RH analoga. Adjuvant hormonal
therapy was applied to 38% either by orchidectomy or
postoperative pharmacological (LH-RH agonist) androgen
withdrawal. Half of the patients received adjuvant radiation
therapy. Postoperative pathological staging, grading, and
adjuvant treatment measures are summarized in Table 2.
The Kaplan-Meier curves describing overall survival,
CSS, and biochemical recurrence are shown in Figures 1, 2,
and 3. Overall survivals at ﬁve and ten years were 95% and
81%. The biochemical recurrence-free survival was 52% at
ﬁveand11%attenyears.Cancer-speciﬁcsurvivalvariedonly
marginally fromOS(100% in ﬁveyears,83% in ten years),as
onlytwooffourdeathsinourcohortwerecausedbyprostate
cancer. Postoperative continence and quality-of-life results
were available through 70% of returned questionnaires in
our study. Regarding postoperative quality of life, 75% of
the patients described their general state of health as good
or very good (SF-12). At last followup, 88% in our study at
used maximum one pad per day (Table 2).
4. Discussion
In the PSA era, the proportion of men treated with RP for
high-risk prostate cancer has decreased while in contrast
the number of patients undergoing surgery for low-risk
cancer is increasing. Nevertheless, the currently used risk
groups remain predictive of patient outcomes [1]. The
pretreatment risk stratiﬁcation for patients diagnosed with
high-risk prostate cancer is commonly based on the classi-
ﬁcation system of D’Amico et al. which includes PSA value
(>20ng/mL), biopsy Gleason’s score (8–10), and clinical
T-stage (cT2c or more) [2]. Based on the same data, for
radical prostatectomy risk, stratiﬁcation is available not onlyAdvances in Urology 3
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Figure 2: Cancer-speciﬁc survival.
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Figure 3: Overall survival.
for biochemical recurrence but also for disease progression
and survival [3]. This observation is crucial as the impact
of biochemical recurrence does not automatically inﬂuence
clinical progression and overall survival. To improve prostate
cancer risk assessment, Cooperberg et al. established a
scoringsystembasedontheCaPSUREdatabasewhichallows
the prediction of clinically more relevant endpoints such
as development of metastases, cancer-speciﬁc mortality, and
o v e r a l ls u rv i v a l[ 4]. In our cohort, we reviewed patients with
a PSA threshold of >40ng/mL in order to assess the outcome
of individuals with an elevated risk proﬁle.
In a retrospective, multi-institutional analysis of 712
patients, Spahn et al. assessed additional high-risk factors for
individuals with pretreatment PSA > 20ng/mL undergoing
RP. Biopsy Gleason’s score ≥8 was identiﬁed as a strong
predictor of progression and survival leading to a cancer-
speciﬁc mortality of 35% in 10 years, whereas biopsy
G l e a s o n ’ ss c o r e ss m a l l e ro re q u a lt o7l e a dt oal o wc a n c e r -
speciﬁc mortality of 5% [5]. In their review, Karnes et al.
specify the outcome of 1513 men from the Mayo Clinic
cohortthatwereclassiﬁedintothehigh-riskgroupaccording
to the D’Amico criteria. Median followup was 7.7 years, and
survival analysis revealed a ten year overall survival of 80%
(95% cancer speciﬁc). Also, 55% of patients were free of
biochemical recurrence in ten years, 90% showed no local
recurrence, and 89% no systemic progression [1].
I no u rs t u d y ,w eo b s e r v e dc o m p a r a b l el o n g - t e r mr e s u l t s
of 95% overall survival at ﬁve years and 81% at 10 years.
Only two patients (4%) died from prostate cancer. The
biochemical recurrence-free rate at ﬁve years was 52%,
however, only 11% at 10 years. Apart from the advantage
of local disease control, 16% of our patients showed an
organ-conﬁned potentially curable tumour stage. Inman et
al. analysed the Mayo Clinic data with PSA values between
50 and 100ng/mL after radical prostatectomy and observed
a lower biochemical relapse rate of 40% at 10 years [6].
Another study group observed PSA failures of 27% at ﬁve
years for patients with elevated PSA of 50 to 100ng/mL [7].
In a retrospective analysis, Gontero et al. found 48 patients
with a PSA ≥ 100ng/mL treated with RP. In this subset of
patients, 8.3% could be cured by surgery alone at a median
followup of 78.8 months. Ten-year cancer-speciﬁc survival
accounted for 79.9%, however, signiﬁcantly decreased in
comparison to lower PSA thresholds in their study [8]. Meng
et al. observed that, in the USA, patients with high-risk
prostate cancer are signiﬁcantly less likely to be treated by
RP than by primary hormonal or radiation therapy [9].
Nevertheless, the aforementioned cancer-speciﬁc and overall
survival rates indicate that high-risk prostate cancer patients
stand to beneﬁt from radical prostatectomy. The variety of
biochemical outcomes in the literature may be the result of
diﬀerent application of adjuvant and salvage therapies in the
respective cohorts. In our study, adjuvant and neoadjuvant
treatment was applied to 38% and 30% of patients. Fifty
percent underwent adjuvant radiation therapy. Walz et al.
investigated the pathological characteristics and rates of
biochemical recurrences after RP in men with advanced
prostate cancer according to the D’Amico classiﬁcation.
Theauthorsobservedfavourablepathology(organ-conﬁned,
negative surgical margins, Gleason’s score ≤7) in 13.7%
of clinical T3 carcinoma, 16.4% of patients with a biopsy
Gleason’s score ≥8, and 21.4% for the D’Amico high-risk
group. Patients with an elevated PSA ≥ 20mg/mL showed
a favourable pathology in 21.6% of cases. The presence of
more than one risk factor led to a decrease in biochemical
recurrence-free survival [10]. In the authors’s opinion, it is
questionable,whetheraPSAof>20or>40isabletodiscerna
high-risk PCA group with regard to operative treatment and
outcome although biochemical relapse rates occur to grow
with high preoperative levels of PSA.
From our own observation and in line with the Mayo
Clinic’s analysis with about 60% of high-risk stratiﬁed
patients presenting with organ-conﬁned stages, allowing
long-term local disease control in 90% of all patients, there
is no rationale to deprive patients of radical surgery [1].
The fact that primary RP goes in line with fundamental
pathologic information oﬀers the possibility to apply adju-
vant treatment to selected patients and to avoid hormonal or4 Advances in Urology
radiation overtreatment. Immediate androgen deprivation
afterradicaltreatmenthasshowntoimprovepatientsurvival
in locally advanced stages [11], and adjuvant androgen
withdrawal has proven to be beneﬁcial for patients with
positive nodal status [12] while adjuvant radiotherapy can
preserve local control in extraprostatic growth and positive
surgicalmargins [13].InaCochrane databasereview,Kumar
et al. found no signiﬁcant improvement on overall survival
by neoadjuvant hormonal treatment prior to RP [14]. As the
patient cohort in our investigation is recruited from 1999 to
2009, in an early subset of patients (17) from 1999 to 2004,
neoadjuvant hormonal treatment has been performed.
Important issues regarding the surgical treatment of
high-risk prostate cancer are operative feasibility, quality
of life, and functional outcome. In a single centre, single
surgeon study of 288 men treated with radical prostatectomy
in a high-risk setting (deﬁned as PSA ≥ 15ng/mL, ≥cT2b or
Gleason’s score 8 to 10), Loeb et al. observed a potency rate
of 62% and a continence rate of 92% within 10 years [15].
Gontero et al. compared a series of patients with clinically
advanced prostate cancer undergoing RP to a control group
of clinically organ-conﬁned disease and found no signiﬁcant
diﬀerences in surgical morbidity apart from transfusion rate,
operation time, and lymphoceles [16]. In our investigation,
75% of patients describe themselves in a good or very good
status of health (SF-12) at followup. Favourable functional
outcome is documented by a rate of 88% of patients requir-
ing at maximum one pad per day. Nevertheless, our analysis
is limited by its retrospective design, the fact that it is based
onsinglecenterdataandthevarietyofapplied(neo)adjuvant
treatment measures. Regarding postoperative Gleason’s
scores, it has to be considered that the number of low Glea-
so n ’ sgrad esisp r es umab l yc o nf ound edb yt umourr egr essio n
due to the preoperatively applied antihormonal treatment.
5. Conclusions
Although RP might be inadequate as solitary therapeutic
approachforhigh-riskprostatecancerinasubsetofpatients,
the procedure allows surgical control with good quality of
life and satisfying functional outcome. Accurate pathologic
information and improved patient selection for individual
adjuvanttreatmentispossible.Eveninindividualspresenting
with elevated PSA ≥ 40ng/mL, RP oﬀers not only long-term
disease control in general but also a curative approach in at
least 16% of patients with organ-conﬁned disease.
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